By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Alios BioPharma 

260 East Grand Avenue
2nd Floor
South San Francisco  California  94080  U.S.A.
Phone: 650-635-5500 Fax: 650-872-0584



Company News
Johnson & Johnson (JNJ) Bags SSF's Alios BioPharma For $1.7 Billion Cash 9/30/2014 6:55:16 AM
Alios BioPharma Announces Upcoming RSV & HCV Scientific Presentations 9/15/2014 2:39:41 PM
Alios BioPharma Presents Data On Its Anti-HCV Nucleotide AL-335 At Special Conference On Hepatitis C 9/15/2014 11:58:51 AM
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014 8:22:35 AM
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) 7/24/2014 1:08:44 PM
South San Francisco's Alios BioPharma Raises $41 Million In Series B Financing 4/7/2014 10:57:52 AM
Alios BioPharma Reports Significant Progress With Its Clinical Program For AL-8176, Its Nucleoside Analog For The Treatment Of Respiratory Syncytial Virus (RSV) 1/13/2014 9:30:08 AM
Alios BioPharma Presented Data on Its First-in-Class Anti-Respiratory Syncytial Virus (RSV) Nucleoside Analogs at the 8th Annual Respiratory Syncytial Virus Symposium 10/1/2012 10:07:39 AM
Vertex Pharmaceuticals (MA) (VRTX) Vows to Fight on With Alios BioPharma Drugs in High-Stakes Hepatitis C Race 1/24/2012 7:24:04 AM
Vertex Pharmaceuticals (MA) (VRTX) and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C 12/9/2011 6:51:43 AM